Cerevel Therapeutics Holdings, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cerevel Therapeutics Holdings, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2019 to 2023.
  • Cerevel Therapeutics Holdings, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $20.9M, a 66.2% increase year-over-year.
  • Cerevel Therapeutics Holdings, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $77.8M, a 81.6% increase year-over-year.
  • Cerevel Therapeutics Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $69.4M, a 79% increase from 2022.
  • Cerevel Therapeutics Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $38.8M, a 62% increase from 2021.
  • Cerevel Therapeutics Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $23.9M, a 128% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $69.4M +$30.6M +79% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 $38.8M +$14.8M +62% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 $23.9M +$13.4M +128% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $10.5M +$2.21M +26.6% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-22
2019 $8.31M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.